Literature DB >> 9427224

Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases.

B Chassande1, J M Léger, A B Younes-Chennoufi, D Bengoufa, T Maisonobe, P Bouche, N Baumann.   

Abstract

Forty cases of polyneuropathy associated with IgM monoclonal gammopathy were retrospectively studied to investigate the relevance of clinical and electrophysiological features to M-protein antibody activity. There were 26 men and 14 women; mean age was 65 +/- 11.7 years at the time of the study. Thirty-nine patients had a symmetrical polyneuropathy, of whom 13 had a predominantly sensory and 17 a purely sensory neuropathy (i.e., 30 sensory neuropathies). The remaining patient had a multifocal mononeuropathy. Electrophysiological studies allowed the polyneuropathies to be classified as demyelinating in 33 cases (82.5%) and axonal in 6 cases. Antibody studies disclosed anti-MAG antibodies in 65% and anti-SGPG antibodies in 82.5% of patients. Anti-MAG antibodies were associated with only demyelinating polyneuropathies. Anti-SGPG antibodies were found in 91% of demyelinating polyneuropathies and 50% of axonopathies. In addition, anti-MAG/SGPG antibody activity was significantly correlated with the subgroup of sensory neuropathies (P < 0.01). Last, antisulfatide antibodies were found at significant titers in 18 cases, and their presence was significantly correlated with anti-MAG/SGPG antibody activity, but not with some clinical/electrophysiological features.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427224     DOI: 10.1002/(sici)1097-4598(199801)21:1<55::aid-mus8>3.0.co;2-f

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  20 in total

Review 1.  Monoclonal IgM autoantibody reactivity in M-IgM peripheral neuropathy.

Authors:  C Caudie
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 2.  Specificity of antiglycolipid antibodies.

Authors:  N Baumann
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

3.  Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients.

Authors:  Marie-Anne Hospital; Karine Viala; Sonia Dragomir; Vincent Levy; Fleur Cohen-Aubart; Jean Neil; Lucile Musset; Sylvain Choquet; Jean-Marc Leger; Véronique Leblond
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 4.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

5.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 6.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

Review 7.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

8.  Clinical, electrophysiological and immunological study of peripheral nerves in Egyptian patients with monoclonal gammopathies.

Authors:  Mohamed M El-Difrawy; Nadia E Zaki; Hazem M Marouf; Mona W Ayad; Ahmed M Farag
Journal:  Int J Hematol       Date:  2011-12-17       Impact factor: 2.490

9.  Immunoglobulin (Ig) M antibody against myelin associated glycoprotein (MAG): A comparison of methods.

Authors:  T D Jaskowski; T B Martins; C M Litwin; H R Hill
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

10.  Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG.

Authors:  A A Ilyas; Y Gu; M C Dalakas; R H Quarles; S Bhatt
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.